Author:
Fernö Mårten,Stål Olle,Baldetrop Bo,Hatschek Thomas,Källström Ann-Christine,Malmström Per,Nordenskjöld Bo,Rydén Stefan
Publisher
Springer Science and Business Media LLC
Reference29 articles.
1. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339: 1-15, 71-85, 1992
2. Fisher B, Dignam J, Bryant J, DeCillis A, Wickerham DL, Wolmark N, Costantino J, Redmond C, Fisher ER, Bowman DM, Deschênes L, Dimitrov NV, Margolese RG, Robidoux A, Shibata H, Terz J, Paterson AHG, Feldman MI, Farrar W, Evans J, Lickley HL: Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen-receptor-positive tumors. J Natl Cancer Inst 88: 1529-1542, 1996
3. Swedish Breast Cancer Cooperative Group: Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. J Natl Cancer Inst 88: 1543-1549, 1996
4. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351: 1451-1467, 1998
5. McGuire WL: An update on estrogen and progesterone receptors in prognosis for primary and advanced breast cancer. In: Iacobelli S et al. (eds) Hormones and Cancer. Raven Press, New York, 1980, pp 337-343
Cited by
74 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献